Ryan Looper

Has grant

Associate Professor

University of Utah
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Ryan Looper is an Associate Professor at the University of Utah, USA. His research focuses on the structural analysis of macrocycles, the development of gold-catalyzed hydroaminations, and the role of small molecules in combating multi-drug resistance. He has contributed to significant advancements in understanding histone demethylases in IDH-mutant cancers and the design of nucleoside antibiotics as universal translation inhibitors.

Recent Grants

Grant: Close

Synthetic and biological investigations of 2-aminoimidazole derived natural products.

Open Date: 2010-05-01

Close Date: 2020-04-30

Grant: Close

Development of Potential Peptidylarginine Deiminase Inhibitors

Open Date: 2005-12-01

Close Date: 2007-06-30

Articles (10)

Year:

2026

Zeteketoxin AB is the only macrocyclic member of the bis‐guanidinium ion toxins, and the only member reported to be more potent than the parent (+)‐saxitoxin. A rationale for this exquisite potency remains difficult to develop due to the scarcity of natural material and a lack of consensus around the specific structure of the toxin itself. A strategy is reported, leveraging an intramolecular Michael addition to forge macrocycles bridging the saxitoxin core, mimicking the proposed structure of zetekitoxin AB. Intriguingly, these analogs do not form a hydrate at C12. Experimental and computational studies suggest that a macrocyclic framework destabilizes the hydrate, casting doubt on the presence of a macrocycle in zetekitoxin. Preliminary activity screening utilizing calcium imaging‐based constellation pharmacology demonstrates several analogs to have potent pharmacological activity similar to (+)‐saxitoxin despite the lack of the C12 hydrated ketone.

Year:

2025

Year:

2025

Oncogenic mutations in isocitrate dehydrogenase (IDH)-1 and -2 occur in a wide range of cancers, including acute myeloid leukemia (AML) and glioma. Mutant IDH enzymes convert 2-oxoglutarate (2OG) to (R)-2-hydroxyglutarate ((R)-2HG)), an oncometabolite that is hypothesized to promote cellular transformation by dysregulating 2OG-dependent enzymes. The only (R)-2HG target that has been convincingly shown to contribute to transformation by mutant IDH is the myeloid tumor suppressor TET2. However, there is ample evidence to suggest that (R)-2HG has other functionally relevant targets in IDH-mutant cancers. Here, we show that (R)-2HG inhibits KDM5 histone lysine demethylases and that this inhibition contributes to cellular transformation in IDH-mutant AML and IDH-mutant glioma. These studies provide the first evidence of a functional link between dysregulation of histone lysine methylation and transformation in IDH-mutant cancers.

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Samuel McBrayer

Assistant Professor

University of Texas Southwestern Department of Pediatrics

UNITED STATES
View details

Peppi Koivunen

Professor

University of Oulu

FINLAND
View details

Cihangir Duy

Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Bailey Miller

Assistant Professor

University of Rhode Island

UNITED STATES
View details

Lucy A. Godley

Northwestern Medicine

UNITED STATES
View details

Keith Ligon

Chief of Neuropathology/Principal Investigator

Dana-Farber Cancer Institute

UNITED STATES
View details